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ABSTRACT:
Introduction: Oral hypoglycemic agents (OHAs) are the most common drugs used in Type 2 Diabetes Mellitus. 
There are various established adverse effects related to their use including hypoglycemia, weight gain, gastrointestinal 
disturbance, lactic acidosis, and fluid retention. However, the pattern of adverse effects related to OHAs in Nepalese 
patients still needs to be explored. Our study aims to determine the pattern of adverse effects resulting from the use 
of OHAs among Type 2 Diabetes mellitus patients and their adherence to the medication. Methods: All diabetic 
patients who met the inclusion criteria were enrolled in the study. After informed consent, patients were interviewed 
and evaluated as per the designed proforma. They were mainly studied for common drug used, adverse effects of the 
drugs, occurrence of hypoglycemia, and adherence to treatment. Results: The study comprised of 183 patients with 
mean age of 58.73 years (SD = 12.95). Fifty-six (30.6%) patients said that they developed adverse effects of drugs 
but only 21 (11.5%) of them reported to their treating physician. Most common adverse effect were related to central 
nervous system such as tingling sensation of hands and feet, dizziness, drowsiness, etc.  Though 91 (49.7%) patients 
had developed symptoms suggestive of hypoglycemia, only 31 (16.9%) knew that it was due to hypoglycemia. 
Majority of the patients (n = 143, 78.1%) administered the drugs as prescribed by the physician. Among the defaulters, 
the most important reasons for failure to properly administer the drugs was forgetfulness in 82.5% (n = 33, N = 40) of 
cases. Among the study variables family history of chronic illness (p = 0.046) and information about adverse effects 
from physician (p = 0.001) had a significant relationship with incidence of adverse effects. Whereas none of them had 
a significant relationship with adherence to hypoglycemic medication. Conclusion: The incidence of adverse effects 
was high with hypoglycemia occurring in 49.7% of the cases, though only one-third of them recognized it to be due to 
hypoglycemia, in the patients with Type 2 Diabetes Mellitus. Family history of chronic illness and information about 
adverse effects from the physician had significant relationship with the incidence of adverse effects of hypoglycemic 
treatment.
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INTRODUCTION:
Diabetes mellitus (DM) is a group of 
metabolic disorders sharing the common underlying 
feature of hyperglycemia. Hyperglycemia in DM 
results from defects in insulin secretion, insulin 
action, or most commonly, both. The chronic 
hyperglycemia and metabolic dysregulation may 
be associated with secondary damage in multiple 
organ system, especially the kidney, eyes, nerves 
and blood vessels.[1] DM has evolved as a global 
health issue, probably due to change in life style, 
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population growth, increasing prevalence of obesity 
and inactivity, which is estimated to affect at least 
300 million people worldwide by 2025.[2] The 
condition can be classified into two types Type 1 and 
Type 2 DM (T2DM) based on its etiopathogenic and 
pathophysiological mechanism. Patients with T2DM 
require medical treatment throughout their life; also, 
they need to maintain proper diet and physical activity 
in order to maintain the sugar level.[3] Different 
factors are responsible for the adverse effects during 
medication. Also, people do not have much idea 
about the management of the sudden adverse effects 
occurring during the medication. In Nepal, there is 
no compulsory law necessitating drug manufacturers 
to submit safety data from the Nepalese population 
prior to approval of the medicines.[4] Inability to 
maintain adherence to treatment regimens, dietary 
modifications, and lifestyle changes has been major 
cause of failure of diabetes management. Our study 
aims to analyze and describe the patterns of adverse 
effects associated with the use of oral hypoglycemic 
agents, adherence to the medication, and factors 
affecting them.
METHODS:
 A cross sectional analytical study was 
conducted among 183 Type 2 diabetic patients 
attending Dhulikhel Hospital (Kathmandu 
University Hospital) and other diabetic clinics in 
Kavre district and Kathmandu Valley, from February 
2014 to October 2014. Patients of all age and sex 
who were diagnosed with T2DM, on treatment either 
admitted or who came for the regular checkup were 
included in this study. The individuals under other 
medications along with anti-diabetic treatment, as 
well as those with other disorders along with T2DM 
were also included. Patients who refused to consent 
to the study were excluded from the study.
 The topic was reviewed and ethical approval 
was granted by Institutional Review Committee of 
Kathmandu University School of Medical Sciences 
(IRC-KUSMS) under protocol approval number 
35/14. The target population meeting the inclusion 
criteria were enrolled in the study and after receiving 
consent, they were interviewed using the preformed 
structured questionnaire. The data information 
included personal history, dietary habits, physical 
activity, drugs administered and adverse effects seen. 
Additional information regarding blood sugar level 
at the time of diagnosis and its recent value, other 
concomitant diseases, occurrence of hypoglycemia 
were included. The data collected were tabulated in 
MS Excel 2007 and were analyzed by IBM SPSS 
Version 16.0. Continuous variables were expressed 
in terms of mean and standard deviation (SD) while 
categorical variables were expressed in terms of 
frequency and percentages. Association between 
categorical variables with adherence status and 
incidence of adverse effects were calculated using 
Pearson Chi-squared test and Fisher exact test 
depending upon number of expected value within 
cells of table. P value less than 0.05 was considered 
significant.
RESULTS:
 The study comprised of 183 patients with 
Type 2 diabetes mellitus (T2DM). There were 116 
(63.4%) males and 67 (36.6%) females. The mean 
age of patients was 58.73 years (SD = 12.95) Mean 
Body Mass Index (BMI) was 23.83 kg/m2 (SD = 
3.95). There were 87 (47.5%) literate and 96 (52.5%) 
illiterate people. Among all, 119 (65%) patients 
used to perform regular exercise. Among those who 
exercised, 78.2% (n = 93, N = 119) had controlled 
blood sugar level.
 Metformin alone was used by 91 (49.7%) 
cases, whereas 24 (13.2%) consumed other oral 
hypoglycemic drugs (sulfonylurea/ Dipeptidyl 
peptidase 4 inhibitors/ α-glucosidase inhibitors/ 
thiazolidinedione), 46 (25.1%) consumed 
combination of metformin and other oral 
hypoglycemic drugs, 15 (8.2%) used insulin alone, 
and seven (3.8%) used metformin and insulin. 
Among all, 77 (42.1%) patients used only anti-
diabetic drugs whereas others took combination of 
anti-diabetic and other non-diabetic drugs. These 
non-diabetic drugs included anti-hypertensive 
agents, statins, vitamins, cephalosporins, etc.
 The study revealed that, among 183 patients, 
56 (30.6%) patients reported adverse effects. Among 
56 patients, 31 (55.6%) said they experienced 
hypoglycemia, eight (14.3%) had tingling sensation 
of hands and feet, six (10.7%) patients each reported 
dizziness and gastrointestinal symptoms, and five 
(8.9%) developed other adverse effects like body 
ache, fatigue, joint pain, and eye irritation. Of 
all patients who developed adverse effects, only 
21 (37.5%) reported about them to their treating 
physician.
 When patients were first explained about the 
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symptoms of hypoglycemia and then asked again 
whether they had experienced such symptoms, 
91 (49.7%) of them agreed that they had such 
symptoms. This showed that 60 (65.9%, N = 91) 
patients who were taking drugs for diabetes did not 
even know the features of hypoglycemia. Only 11 
(6%) of the total patients were informed about the 
adverse effects of the oral hypoglycemic drugs by 
their treating physician.
 Majority of the patients (n = 143, 78.1%) 
administered the drugs as per the physician’s 
recommendation. Among the individuals who did 
not follow the physician’s recommendation on drug 
consumption, most of them (n = 33, N = 40, 82%) 
said it was due to forgetfulness, six (15%) due to 
carelessness, and mere one (3%) due to financial 
problems.
 According to the American Diabetes 
Association, the blood sugar level of the diabetic 
patients must be monitored in every three months 
with the assessment of glycated hemoglobin 
(HbA1c).[5] The study defines a patient to be aware 
if s/he goes for regular checkup of blood sugar level 
at the interval of three months or less than that. 
Among the studied patients, 79.24% (n = 145) of 
them were found to be aware.
 Association between various variable and 
adherence to oral hypoglycemic agents is shown 
in Table 1. There was no significant association of 
adherence to oral hypoglycemic agents with any of 
the variables.
 Relationship between occurrence of adverse 
effects and various variables is shown in Table 2. 
Family history of chronic illness and information 
about adverse effect from physician had significant 
relationship with the occurrence of adverse effects. 
Patients with family history of chronic illness were 
more likely to have experienced adverse effects 
of hypoglycemic medication compared to those 
without family history of chronic illness. Similarly, 
patients who received information about adverse 
effects of drugs from physicians were more likely to 
have experienced adverse effects of hypoglycemic 
medication as compared to those not receiving 
information about adverse effects. None of the 
other variables had significant relationship with 
occurrence of adverse effects.
DISCUSSION:
 The incidence of type 2 Diabetes mellitus 
Table 1: Association between various variables and medication
              adherence
Variables Adherentn (%)
Non 
Adherent
n (%)
X2 df p
Sex
Male 87(75.0) 29(25)
0.75 1 0.39
Female 54(80.6) 13(19.4)
Literacy Status
Literate 70(76.1) 22(23.9)
0.1 1 0.76
Illiterate 71(78.0) 20(22.0)
Marital Status#
Unmarried 3(75.0) 1(25.0)
0.6# 0.97
Married 119(76.3) 37(23.7)
Widow 11(84.6) 2(15.4)
Widower 8(80.0) 2(20.0)  
Status of Employment
Unemployed 76(81.7) 17(18.3)
2.3 1 0.13
Employed 65(72.2) 25(27.8)
Drinking status
Non Drinker 97(77.0) 29(23.0)
0.2  0.93Drinker 24(75.0) 8(25.0)
Past Drinker 20(80.0) 5(20.0)
Dietary Habits
Vegeterian 20(90.9) 2(9.1)
2.7 1 0.1
Non Vegeterian 121(75.2) 40(24.8)
Family History of Chronic Illness
Yes 62(78.5) 17(21.5)
0.16 1 0.69
No 79(76.0) 25(24.0)
Practice of Exercise
Yes 98(79.0) 26(21.0)
0.86 1 0.36
No 43(72.9) 16(27.1)
Information about adverse effect from Physician
Yes 11(78.6) 3(21.4)
0.02 1 0.89
No 130(76.9) 39(23.1)
Concomitant Disease
Present 80(82.0) 18(18.0)
3.06 1 0.08 
Absent 59(71.1) 24(28.9)
Awareness on the condition
Yes 111(79.3) 29(20.7)
1.69 1 0.19
No 30(69.8) 13(30.2)
#Fisher's Exact Test performed
(DM) was found to be more in male population as 
compared to female population. This result was 
similar to result of other studies done in different 
countries where prevalence of type 2 DM was less 
in female as compared to male.[6] This might be 
due to more sedentary lifestyle in male, resulting in 
increased obesity. Moreover, Body fat distribution 
differs with the sex, where higher proportion of 
visceral and hepatic fat compartments in male are 
associated with insulin resistance.[6] Whereas, in 
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Table 2: Association between various variables and
              incidence of adverse effects
Variables
Adverse 
Effect
n (%)
No Adverse 
Effect
n (%)
χ2 df p
Sex
Male 22(32.8) 45(67.2)
0.25 1 0.62
Female 34(29.3) 82(70.7)
Literacy Status
Literate 26(28.6) 65(71.4)
0.35 1 0.56
Illiterate 30(32.6) 62(67.4)
Marital Status#
Unmarried 0(0.0) 4(100.0)
1.85# 0.62
Married 50(32.1) 106(67.9)
Widow 4(30.8) 9(69.2)
Widower 2(20.0) 8(80.0)  
Status of Employment
Unemployed 32(34.4) 61(65.6)
1.29 1 0.26
Employed 24(26.7) 66(73.3)
Drinking status
Non Drinker 40(31.7) 86(68.3)
0.57 2 0.75Drinker 8(25.0) 24(75.0)
Past Drinker 8(32.0) 17(68.0)
Dietary Habits
Vegetarian 8(36.4) 14(63.6)
0.39 1 0.53
Non Vegetarian 48(29.8) 113(70.2)
Family History of Chronic Illness
Yes 18(22.8) 61(77.2)
3.99 1 0.046*
No 38(36.5) 66(63.5)
Practice of Exercise
Yes 35(28.2) 89(71.8)
1.02 1 0.31 
No 21(35.6) 38(64.4)
Information about adverse effect from Physician
Yes 10(71.4) 4(28.6)
11.9 1 0.001*
No 46(27.2) 123(72.8)
Concomitant Disease
Present 34(34.0) 66(66.0)
1.2 1 0.27 
Absent 22(26.5) 61(73.5)
Awareness on the condition
Yes 43(30.7) 97(69.3)
0.004 1 0.95 
No 13(30.2) 30(69.8)
#Fisher's Exact test performed       *statistically significant
female, there is more subcutaneous and peripheral 
fat, which is associated with insulin sensitivity and 
are protective against Type 2 Diabetes. This make 
female less susceptible to Type 2 Diabetes than their 
male counterparts, who suffer from diabetes at lower 
mass index than female. 
 Analysis of the T2DM patients showed 
almost equal percentage of literate and illiterate 
participants in our study. This may be due to the 
fact that even if the patients are illiterate, they may 
have proper diabetic knowledge. This is supported 
by study done in USA where there was no direct 
association of glycemic control with literacy but 
association was seen with diabetic knowledge.[7] In 
our study, among 119 patients who performed regular 
exercise, 78.15% of them had controlled blood sugar 
level. Exercise has shown to protect individuals 
from developing metabolic syndrome.[8] It reduces 
insulin resistance that helps in regulation of blood 
glucose level, lowers uric acid and triglycerides 
whereas there is increase in the HDL cholesterol 
ratio.[9]
 Polypharmacy was found to be common 
among the patients. Since patient suffering from 
T2DM commonly show other concomitant diseases 
like hypertension, dyslipidemia, polypharmacy is 
common.[5] Polypharmacy has been often linked with 
decreased medication adherence is also associated 
with potential drug interactions and adverse effects.
[10] Polypharmacy comprises of multiple drugs 
with complex drug schedule which are often difficult 
to be followed by patients which may be the cause of 
poor adherence.[11] However, reduction in number 
of drug might cause under treatment, specially 
in T2DM patients with dyslipidemia, resulting in 
serious consequences.[10] Thus, pharmacist may 
have significant role on optimization of the drug and 
dosage regimen for maximum benefit of patient.
 Nearly half (49.7%) of the individuals 
encountered episodes of hypoglycemia in the 
study. Among these individuals many of them 
used metformin with other hypoglycemic agents. 
This might be the reason for higher incidence 
of hypoglycemia as in a combination therapy, 
symptom of hypoglycemia was found to be related 
to sulfonylureas with no or limited influence of 
metformin.[12] The patients were also under other 
medications such as antihypertensive like, statins 
and other drugs like vitamins, cephalosporins, 
etc. Use of ACE inhibitor like enalapril has been 
found to be associated with an increased risk of 
hypoglycemia.[13] Additionally, a study has shown 
that concomitant use of amlodipine and telmisartan 
along with metformin and glimpiride has shown to 
cause hypoglycemia.[14] As our study comprises 
patients concomitantly using these drugs with 
antidiabetic agents, hypoglycemia observed may 
also be due to these drugs. Even though metformin 
is mostly used, hypoglycemia is still seen. This may 
be due to the high incidence of missing of meal. It 
is supported by a study which reports that missing 
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or irregular intake of meal is the most frequent 
behavioral factor causing individual episodes of 
hypoglycemia.[15] Although people were aware 
about taking the medication, they were unaware 
that along with medication proper diet must also be 
taken.
 The study revealed that among 183 patients, 
56 (30.6%) of the patients developed various side 
effects. The major adverse effect was found to be 
hypoglycemia (n = 31), and other were tingling 
sensation, dizziness, gastrointestinal disorder like 
abdominal discomfort, diarrhea, and other effects 
like fatigue, joint pain and eye irritation. However, 
when patients were explained about symptoms 
of hypoglycemia, 49.7% (n = 91) of the patients 
reported occurrence of those symptoms. This 
showed that 65.9% (n = 60, N = 91) patients were 
not aware about the features of hypoglycemia and 
failed to distinguish symptoms of hypoglycemia 
as adverse effects. In a study, insulin and the 
sulfonylureas (SUs) were seen as the main drugs 
leading to hypoglycemia in patients with T2DM.
[16] The major risk factors of hypoglycemia include 
age where studies have shown that awareness is less 
common in elderly patients with T2DM. Other risk 
factors for hypoglycemia include missing meals, 
coronary artery disease, renal impairment, insulin 
or sulphonyl urea (SU) treatment, and a history of 
severe hypoglycemia. Insulin therapy is associated 
with weight gain and hypoglycemia and shows other 
adverse effects like local reactions such as swelling, 
erythema and lipodystrophy, allergy and edema.[17]
 Metformin showed adverse effects 
associated with typically mild, transient and of 
gastro-intestinal (GI) origin including metallic taste, 
diarrhea, nausea, vomiting, anorexia and a variety 
of other GI symptoms such as bloating. Metformin 
does not induce hypoglycemia; however, the risk 
of hypoglycemia increases when metformin is 
used in combination with other therapeutic agents. 
Continuous use of metformin causes a vitamin 
B12 deficiency, since it decreases absorption of 
the vitamin.[18] In a comparative trial, the adverse 
events like weight gain, hypoglycemia, and GI 
effects were found to occur more in combination 
of metformin and glibenclamide as compared to 
metformin with glimepiride.[19] Other adverse 
effects reported related to SUs are dermatological 
effects like rash, purpura and pruritus, GI effects 
like nausea, vomiting, cholestatic jaundice, and 
hyperinsulinemia. Study also shows that some 
patients exerting hypersensitive reactions like 
allergy to sulfonamide medications may exhibit 
cross-reactivity with sulfonylureas.[20]
 The meglitinides may possess a lower 
incidence of hypoglycemia and weight gain. A study 
showed that diarrhoea occurred less frequently 
and hypoglycemia occurred more frequently but 
rarely severe with the drug.[21] Hypoglycemia was 
observed in relatively few thiazolidinediones (TZDs) 
treated patients, however increased insulin dosing 
in combination with glitazone resulted in increased 
risk of hypoglycemia. TZDs have caused increase 
in body weight and redistribution of adipose tissue 
from visceral site to subcutaneous regions, so this 
may cause worsening of existing peripheral edema 
and can also precipitate or worsen congestive heart 
failure.[22]
 The adverse effects encountered during 
the therapy may not have been only due to the 
antidiabetic agents but could have been resulted 
from the administration of other drugs such as 
antihypertensive like, statins and other drugs like 
vitamins, cephalosporins, etc. Angiotensin receptors 
blockers (ARB) like losartan, telmisartan, etc, 
β- blocker like metoprolol, ACE inhibitors like 
enalapril, ramipril, etc and calcium channel blockers 
like amlodipine. ARB like losartan has been reported 
to cause side effects like dizziness, lightheadedness, 
weakness and physical problems including diarrhea, 
muscle cramp and back or leg pain. These side 
effects can be misinterpreted as side effects resulted 
from the antidiabetic agents. The early vasodilating 
action of the calcium channel blockers have shown 
to cause effects like headache dizziness, nausea, 
palpitation and diarrhea.[23]
 Our study revealed that only few (n = 40, 
21.9%) of the diabetic patients did not follow the 
medical advice regarding the doses of the drugs. 
Among those patients, the most common cause of 
inconstancy was forgetfulness. Similar result was 
shown by a study where forgetfulness and negligence 
were found to be the major reasons for inconstancy.
[24] Our study comprised more number of elderly 
patients and people get more forgetful as they age. 
So, this might be the reason that forgetting behavior 
of the patient which causes medical inconstancy.
 Upon Chi-squared analysis, none of the 
variables that we considered were significantly 
associated with adherence status. It included factors 
like awareness on the disease condition, drinking 
habits, dietary habits, practice of exercise, information 
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from physician about adverse effects and other non-
modifiable variables like sex, literacy status, marital 
status, employment status, concomitant disease, and 
family history of chronic illness. Similarly, in other 
studies as well, sex and education level has not been 
frequently associated with level of patient adherence.
[25,26] Whereas, level of education has been 
reported to determine adherence status.[27] Though 
not statistically significant, there are more number 
of adherent patients who have received information 
regarding adverse effects from their physicians and 
are more aware about their condition. Patients are 
said to have specific mental models while following 
their treatment regimen and are thus related with 
adherence.[28] As a result, it is recommended to 
explore more modifiable factors like health literacy, 
patient physician interaction, and health perception 
in relation with adherence.[29]
 In case of incidence of adverse effects, 
information received from the physician regarding 
adverse effect (p = 0.001) and family history 
of chronic illness (p = 0.046) were found to be 
significantly associated with incidence of adverse 
effects. Other factors were not found to have 
statistically significant association with incidence 
of adverse effects. This scenario enhances need 
for enhancing communication between patient and 
the physician. Collaborative relationship between 
patient and physician has been reported to improve 
patient adherence and thus the clinical outcome.[30] 
Patients should be given information about what can 
be done if adverse effects are bothersome in addition 
to the objective of medication.[31] Causes of adverse 
effects can often be multifactorial and genetics of a 
patient among the foremost.[32] In our study, family 
history of chronic illness seems to have indirect 
association with incidence of adverse effects may be 
due to the common gene pool within a family having 
history of chronic illness.
 The study was a cross-sectional and was 
limited only to small area. It also shared several 
limitations as patients’ compliance was determined 
only by few parameters. However, this study provided 
us knowledge about the adverse effect pattern 
encountered by Nepalese population suffering from 
T2DM who were under medication.
CONCLUSION:
 Oral hypoglycemic agents may cause various 
adverse effects in our study. The most common adverse 
effect seen in diabetic patient was hypoglycemia and 
majority of them were caused by missing of meal. 
Even though various side effects were experienced 
by the patients, very few reported about them to their 
physician. Also, only few were informed about the 
adverse effects by their physicians in pre-medication 
stage and this factor had a significant association 
with incidence of adverse effects. Physicians can 
inform patients about the possible adverse effects, 
which might help patients to cope with unpleasant 
adverse effects and thus enhance adherence.
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